Goldman Sachs Group Inc. lifted its stake in shares of Merus Labs International Inc (NASDAQ:MSLI) (TSE:MSL) by 3,995.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,093,541 shares of the company’s stock after acquiring an additional 1,066,837 shares during the period. Goldman Sachs Group Inc.’s holdings in Merus Labs International were worth $1,378,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of the company. Kassirer Asset Management Corp bought a new stake in shares of Merus Labs International during the second quarter worth $2,054,000. OMERS ADMINISTRATION Corp bought a new position in Merus Labs International in the second quarter valued at $1,358,000. Vanguard Group Inc. bought a new position in Merus Labs International in the second quarter valued at $756,000. Finally, Glazer Capital LLC bought a new position in Merus Labs International in the second quarter valued at $496,000. 19.69% of the stock is owned by institutional investors.
Shares of Merus Labs International Inc (MSLI) remained flat at $$1.30 on Friday. Merus Labs International Inc has a one year low of $0.70 and a one year high of $1.33. The company has a debt-to-equity ratio of 0.50, a current ratio of 0.80 and a quick ratio of 0.54.
Merus Labs International Profile
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Receive News & Ratings for Merus Labs International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc and related companies with MarketBeat.com's FREE daily email newsletter.